3652 results for «231»
3652 results
The metal-free strategy: shaping the new era of hybrid vessel restoration with DCB and BRS
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the emerging metal-free strategy in coronary intervention, combining drug-coated balloons (DCB) and bioresorbable scaffolds (BRS) to support a “leave-nothing-behind” approach to vessel restoration.
It focuses on lesion preparation, scaffold sizing and deployment, and the integration of hybrid therapies to optimise procedural outcomes....
Disrupting the aorta and valves: the next transcatheter wave
18 May 2026 – From EuroPCR 2026
Delve into the next wave of transcatheter interventions disrupting the aorta and valves. This session covers pioneering minimally invasive ascending aortic repair, novel polymeric aortic valve implants, and innovative devices for tricuspid repair and leaflet replacement.
Rethinking stentless PCI strategy - Improving outcomes with Bioadaptor
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores contemporary PCI strategies through the concept of stentless intervention using the Bioadaptor device in complex coronary disease.
It highlights the bioadaptive design features of Bioadaptor and reviews the supporting clinical evidence, with a focus on how this technology may influence procedural outcomes.
The...
The Physiology Course - Introduction
18 May 2026 – From EuroPCR 2026
The Physiology Course introduction welcomes participants and provides an overview of the importance of coronary physiology, outlining the program designed in collaboration with EuroPCR.
How to become a CHAMPION in LAA closure
19 May 2026 – From EuroPCR 2026
This session reviews the latest CHAMPION AF trial data and its implications for left atrial appendage (LAA) closure in patients with atrial fibrillation.
It explores how emerging evidence may influence clinical practice and patient selection, and how LAA closure could evolve across different atrial fibrillation populations.
A recorded...
The physiological mindset: foundations every modern operator must own
18 May 2026 – From EuroPCR 2026
This session delves into the fundamental principles governing coronary blood flow regulation, emphasizing coronary autoregulation and the influence of epicardial haemodynamics on vascular morphology. Participants deepen their understanding of coronary physiology beyond formulas, exploring the intersection of physiology and atherosclerosis.
Physiology in the real world: how to measure, when to trust it, what to do?
18 May 2026 – From EuroPCR 2026
This session provides comprehensive insights into coronary physiology assessment tools, emphasizing techniques for reliable haemodynamic measurements and exploring clinical considerations surrounding coronary spasms and myocardial bridges.
Management of a patient with complex multivessel disease involving bifurcations
19 May 2026 – From EuroPCR 2026
Complex multivessel coronary disease involving bifurcations requires careful procedural planning, imaging guidance and tailored stent strategies.
This EuroPCR 2026 session combines live educational case with insights from the NAGOMI COMPLEX study to explore contemporary approaches to complex PCI. A key focus is placed on the role of...
PCR Tokyo Valves 2026: Your travel guide featuring upcoming exclusive booking services and special deals.
Percutaneous or surgical management of post-infarction ventricular septal defects: The United Kingdom National Registry
17 Sep 2022
Elad Asher provides his take on the UK National Registry which was presented at the TCT congress 2022 by Joel Peter Giblett on behalf of the UK PIVSD investigators.
Author
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
EuroPCR 2026 – Long-term mortality following revascularisation for left main disease
20 May 2026
Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is a meta-analysis of long-term data from 4 randomised trials investigating...
